In the last trading session, 1.08 million Aquestive Therapeutics Inc (NASDAQ:AQST) shares changed hands as the company’s beta touched 1.96. With the company’s per share price at $3.31 changed hands at $0.06 or 1.85% during last session, the market valuation stood at $328.78M. AQST’s last price was a discount, traded about -75.23% off its 52-week high of $5.80. The share price had its 52-week low at $2.12, which suggests the last value was 35.95% up since then. When we look at Aquestive Therapeutics Inc’s average trading volume, we note the 10-day average is 1.54 million shares, with the 3-month average coming to 1.54 million.
Analysts gave the Aquestive Therapeutics Inc (AQST) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.11. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended AQST as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight.
Aquestive Therapeutics Inc (NASDAQ:AQST) trade information
Instantly AQST was in green as seen at the end of in last trading. With action 0.61%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 36.78%, with the 5-day performance at 0.61% in the green. However, in the 30-day time frame, Aquestive Therapeutics Inc (NASDAQ:AQST) is 18.64% up. Looking at the short shares, we see there were 12.0 million shares sold at short interest cover period of 5.96 days.
The consensus price target for the stock as assigned by Wall Street analysts is 7, meaning bulls need an upside of 52.71% from its current market value. According to analyst projections, AQST’s forecast low is 7 with 7 as the target high. To hit the forecast high, the stock’s price needs a -111.48% plunge from its current level, while the stock would need to soar -111.48% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 27.90%. The 2025 estimates are for Aquestive Therapeutics Inc earnings to decrease by -37.04%, but the outlook for the next 5-year period is at 20.57% per year.
AQST Dividends
Aquestive Therapeutics Inc is expected to release its next quarterly earnings report on 2025-May-12.
Aquestive Therapeutics Inc (NASDAQ:AQST)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 5.62% of Aquestive Therapeutics Inc shares while 48.76% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 51.66%. There are 48.76% institutions holding the Aquestive Therapeutics Inc stock share, with BRATTON CAPITAL MANAGEMENT, L.P. the top institutional holder. As of 2024-06-30, the company held 10.7918% of the shares, roughly 9.81 million AQST shares worth $25.51 million.
VR ADVISER, LLC holds the second largest percentage of outstanding shares, with 6.1109% or 5.56 million shares worth $14.44 million as of 2024-06-30.
